Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AbCellera Biologics ( (ABCL) ) has provided an announcement.
AbCellera Biologics reported its financial results for the third quarter of 2025, highlighting the start of activities at its new clinical manufacturing facility and substantial completion of platform investments. The company ended the quarter with $680 million in available liquidity, despite a net loss of $57.1 million. Key developments included the appointment of a new Chief Medical Officer and progress in Phase 1 clinical trials for its lead programs. The company also reported an increase in partner-initiated program starts and molecules advanced into the clinic, reflecting its strategic focus on expanding its pipeline.
The most recent analyst rating on (ABCL) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on AbCellera Biologics stock, see the ABCL Stock Forecast page.
Spark’s Take on ABCL Stock
According to Spark, TipRanks’ AI Analyst, ABCL is a Neutral.
AbCellera Biologics’ overall score reflects its strong liquidity and strategic pipeline advancements, which are offset by ongoing financial challenges, including negative profitability and cash flow issues. The technical indicators suggest a cautious outlook, while the valuation remains a concern due to the negative P/E ratio.
To see Spark’s full report on ABCL stock, click here.
More about AbCellera Biologics
AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women’s health, immunology, and oncology.
Average Trading Volume: 5,174,169
Technical Sentiment Signal: Buy
Current Market Cap: $1.46B
For detailed information about ABCL stock, go to TipRanks’ Stock Analysis page.